Skip to main content

Table 1 Demographic and clinical characteristics of patients with inflammatory arthritis who discontinued therapy according to clinical remission

From: Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry

 

Total

Disc. due to rem

No disc. due to rem

P value**

N

3366

80

3286

 

Median duration of follow-up (years) (IQR:p25–p75)

3.04 (1.16–6.95)

5.57 (3.73–8.89)

2.98 (1.16–6.87)

 < 0.001

Age, years mean (SD)

51.8 (13.1)

49.9 (15.1)

51.8 (13.0)

0.202

Female sex, n (%)

2133 (63.4)

43.0 (53.8)

2090 (63.6)

0.071

Age at diagnosis, mean (SD)

43.2 (13.7)

43.3 (14.4)

43.2 (13.6)

0.950

Disease duration, years, mean (SD)

8.6 (8.4)

6.6 (4.7)

8.6 (8.4)

0.036

Smoker, n (%)

Never

331 (9.8)

68.0 (85.0)

2165 (65.9)

0.004

Current

2233 (66.3)

9.0 (11.3)

695 (21.2)

Previous

704 (20.9)

2.0 (2.5)

329 (10.0)

Charlson Comorbidity Index, mean (SD)

2.1 (1.4)

1.8 (1.5)

2.1 (1.4)

0.143

Previous biologic DMARD, n (%)

First-line

1955 (58.1)

47.0 (58.8)

1908 (58.1)

0.902

Second-line

1411 (41.9)

33.0 (41.3)

1378 (41.9)

Concomitant DMARD

MTX

1414 (63.7)

25.0 (44.6)

1389 (64.2)

0.003

LFN

639 (33.9)

11.0 (22.0)

628 (34.2)

0.071

SSZ

174 (10.6)

5.0 (10.0)

169 (10.6)

0.893

Time on treatment with the previous biologic agent, mean (SD)

24.9 (34.3)

50.2 (40.0)

24.3 (33.9)

 < 0.001

Biologic discontinued, n (%)

TNF-i

2575 (76.5)

72 (90.0)

2503 (76.2)

0.304

IL6-i

197 (5.9)

3 (3.8)

194 (5.9)

 

CD20-i

189 (5.6)

2 (2.5)

187 (5.7)

 

JAK-i

70 (2.1)

0 (0)

70 (2.1)

 
 

IL17-i

109 (3.2)

0 (0)

109 (3.3)

 

IL12-23-i

28 (0.8)

0 (0)

28 (0.9)

 

Apremilast

57 (1.7)

0 (0)

57 (1.7)

 

Abatacept

134 (4.0)

3 (3.8)

131 (4.0)

 

RF-positive, n (%)

828 (24.6)

9 (11.3)

819 (24.9)

0.002

ACPA-positive, n (%)

758 (36.8)

3 (8.6)

755 (37.3)

0.112

HLA-B27-positive, n (%)

671 (19.9)

18 (22.5)

653 (19.9)

0.203

Moderate-high disease activity at initiation of biologicsa

457 (17.8)

9 (17.0)

448 (17.8)

0.874

  1. Data are shown as mean (SD), except for categorical variables, which are shown as total number (percentage)
  2. Disc Discontinuation, Rem Remission, MTX Methotrexate, LFN Leflunomide, SSZ Sulfasalazine, i inhibitor, RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibody
  3. aModerate-high disease activity was defined as DAS28 ≥ 3.2 or BASDAI ≥ 4, depending on the disease
  4. **p-value for possible differences between the group of patients who suspend treatment owing to remission and the rest of the population (patients receiving ongoing treatment or who had discontinued treatment for other reasons)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us